Comparison between hemofiltration and hemodiafiltration in a long-term prospective cross-over study.
The objective of the study was to compare the convective treatment modes, on-line hemofiltration (HF) and on-line hemodiafiltration (HDF), regarding cardiovascular tolerance and effects on blood pressure, when applied under similar conditions in stable dialysis patients. 39 clinically stable dialysis patients were treated with HD for 6 months (run-in period), followed by HF and HDF in random order for 2x6 months. Similar biocompatibility (same membrane and fluid quality), similar treatment time and urea Kt/V were achieved using AK100/200 ULTRA machines, polyamide membranes in low-flux and high-flux versions and appropriate adjustment of blood flow rate (Qb) and dilution ratio (Qb/Qinf). Predilution was used for HDF (target dilution ratio = 2/1 ) as well as for HF (target dilution ratio = 1/1). 30 patients completed the study; 5 dropped out for non-study related reasons and 4 for non-compliance. Treatment with HF in comparison to HDF showed fewer hypotension episodes during the sessions per patient and month (HF: 0.5, HDF 1.1; p = 0.017), less plasma expander administration per patient and month (HF: 35.9 ml, HDF: 103.1 ml; p = 0.035), fewer episodes of intra-session headache (HF: 0.1, HDF: 0.4; p = 0.06), and higher pre-session MAP (HF: 98.4 mmHg, HDF: 93.8 mmHg; p = 0.037). No significant difference was found in inter-treatment weight gain, post-session MAP, or pre-session plasma sodium. HF and HDF provide good control of intra-session symptoms and blood pressure in stable patients. Treatment with HF resulted in a significant reduction in intra-session hypotension and a slight but significant increase in pre-session MAP, caused by an increase in systolic BP without any effect on the prevalence of hypertension or the dose of antihypertensive drugs, all compared to HDF.